4 years ago

Ori Biotech Raises Over USD100 Million in Series B Funding

  • Ori Biotech Ltd., a London and New Jersey-based leader in cell and gene therapy (CGT) manufacturing technology, secured over USD 100m in Series B funding

  • The round was led by Novalis LifeSciences with participation from Puhua Capital and Chimera Abu Dhabi and existing investors Amadeus Capital Partners, Delin Ventures, Northpond Ventures and Octopus Ventures

  • The company will use the funds to further expand key personnel across all functions, in order to transition through pre-commercialization to the launch of its innovative CGT manufacturing platform

  • Ori Biotech was founded in 2015 by Dr Farlan Veraitch (UCL) and led by Jason C

  • Foster, CEO

  • The company provides a proprietary, full stack manufacturing system that closes, automates, digitizes and standardizes CGT manufacturing

  • The management team also includes Jason Jones (Miltenyi), Kevin Gordon (Tmunity), Stuart Milne (Cytiva), Tom Heathman (Minaris), David Smith (Minaris), Lee Unroe (Indivior), Chris Mason (AVROBIO), Paul Meister (ThermoFisher), and Annalisa Jenkins (Dimension Therapeutics).

      • ProblemHealthcare

      "making cell and gene therapy manufacturing more efficient and standardized"

      Solution

      "providing a full stack manufacturing system that automates and digitizes the process"

      Covered on